Davis Select Financial 주식 가격. DFNL - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

프리미엄

가격

27.80

매수가

19.92

매도가

35.71

거래량

0.00 일간 변동폭 0.00

0.00 52주 범위 0.00

market_cap

164.02M

전일 종가

27.80

개장가

최근 거래 시간

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

발행 주식

5,900,000

배당수익률

주가수익률

-207.31

주당순이익(EPS)

-0.13

매출

4.81M

순이익

-791k

The investment seeks long-term growth of capital. The fund's investment adviser uses the Davis Investment Discipline to invest the fund's portfolio principally in common stocks (including indirect holdings of common stock through depositary receipts) issued by foreign companies, including countries ... The investment seeks long-term growth of capital. The fund's investment adviser uses the Davis Investment Discipline to invest the fund's portfolio principally in common stocks (including indirect holdings of common stock through depositary receipts) issued by foreign companies, including countries with developed or emerging markets. The fund may invest in large, medium or small companies without regard to market capitalization. 더 보기

섹터

Mgmt Invt Offices, Open-end

산업

Mgmt Invt Offices, Open-end

본부

Wilmington, Delaware, USA

설립됨

1970

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its...

FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States...

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the...

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted...

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file...

Mesoblast Corporate Presentation at Investor Conference

NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference...

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024

NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report...

FDA Commentary Sends Biotech Soaring During Premarket Hours

A biotech stock that has seen some pretty wild price swings as of late is turning heads so far during Tuesday’s premarket after the company was notified by the U.S. FDA that To read the full...

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has...

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

기호	가격	볼륨
BBLGBone Biologics Corporation	US$ 3.35 (55.09%)	21.32M
RDHLRedhill Biopharma Ltd	US$ 0.5696 (48.29%)	46.91M
BIMIBIMI International Medical Inc	US$ 0.5802 (38.14%)	1.62M
IMRXImmuneering Corporation	US$ 1.49 (31.86%)	11.52M
CDNACareDx Inc	US$ 25.00 (25.06%)	32.62k
VWEVintage Wine Estates Inc	US$ 0.0326 (-37.19%)	6.41M
ALXOALX Oncology Holdings Inc	US$ 3.12 (-35.00%)	653.95k
NCNCnoco noco Inc	US$ 0.2116 (-26.27%)	2.26M
ATECAlphatec Holdings Inc	US$ 7.93 (-21.49%)	75.43k
NVANova Minerals Limited	US$ 4.18 (-18.20%)	19
HUGEFSD Pharma Inc	US$ 0.1215 (20.30%)	49.08M
RDHLRedhill Biopharma Ltd	US$ 0.5696 (48.29%)	46.91M
BBLGBone Biologics Corporation	US$ 3.35 (55.09%)	21.32M
NVDANVIDIA Corporation	US$ 119.16 (1.83%)	14.69M
RCMR1 RCM Inc	US$ 14.05 (9.08%)	13.23M

기호

가격

볼륨

HUGEFSD Pharma Inc

US$ 0.1215

(20.30%)

49.08M

RDHLRedhill Biopharma Ltd

US$ 0.5696

(48.29%)

46.91M

BBLGBone Biologics Corporation

US$ 3.35

(55.09%)

21.32M

NVDANVIDIA Corporation

US$ 119.16

(1.83%)

14.69M

RCMR1 RCM Inc

US$ 14.05

(9.08%)

13.23M

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Davis Select Financial (DFNL)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

Davis Select Financial 정보

DFNL 최신 뉴스

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024

FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week

Mesoblast Corporate Presentation at Investor Conference

Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024

FDA Commentary Sends Biotech Soaring During Premarket Hours

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Davis Select Financial (DFNL) 시세

Davis Select Financial (DFNL)

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

주요 통계 및 세부정보

Davis Select Financial 정보

DFNL 최신 뉴스

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP